IP Library Granted Patent US 9,404,149
Granted Patent B2
US 9,404,149 · App. 13/383,141 · Granted Aug 2, 2016

Composition, kits and methods for the detection of point mutations and SNPs

Inventors: Daniel Adlerstein (Arese, IT); Giulia Amicarelli (Parabiago, IT); Giulia Minnucci (Milan, IT)
Assignee: BIOTRIN INTERNATIONAL LIMITED
C12Q1/6858
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,404,149
App. No.
13/383,141
Granted
Aug 2, 2016
Kind
B2
Abstract

The present invention refers to a method for detecting a point mutations of a nucleotide sequence by an improvement of the LAMP (loop amplification mediated polymerization) amplification method, as well as to a set of primers and kit therefor. As a non limitative embodiment, the invention refers to the G1849T mutation of the JAK2 gene.

Claims (29)

1. A set of primers for detecting, by loop mediated isothermal amplification, the presence of a point mutation in a target nucleic acid molecule in a background of wild type nucleic acid molecules, the set of primers comprising:

i. a first outer primer F3 and a second outer primer B3;

ii. a first inner primer FIP and a second inner primer BIP,

wherein FIP comprises a 3′ nucleic acid sequence F2 and a 5′ nucleic acid sequence F1c and BIP comprises a 3′ nucleic acid sequence B2 and a 5′ nucleic acid sequence B1c, wherein F1c is able to recognize and hybridize to a region of the target nucleic acid molecule designated as F1 and wherein B1c is able to recognize and hybridize to a region of the target nucleic acid molecule designated as B1, and wherein F1 and B1 are different regions located on opposite strands of the target nucleic acid molecule,

wherein F2 is complementary to a region of the target nucleic acid molecule designated as F2c and B2 is complementary to a region of the target nucleic acid molecule designated as B2c,

wherein F2c and B2c are non-overlapping regions located on opposite strands of the target nucleic acid molecule,

wherein either B2c is downstream of the point mutation or F2c is upstream of the point mutation, and wherein

if B2c is downstream of the point mutation, then said point mutation is located in the F2c sequence or between the F2c sequence and the F1c sequence, or

if F2c is upstream of the point mutation, then said point mutation is located in the B2c sequence or between the B2c sequence and the B1c sequence;

iii. a stem-loop mutant extensible primer comprising:

a central loop sequence complementary to a region of a target nucleic acid molecule comprising the point mutation, and

a 5′ end sequence and a 3′ end sequence which are complementary to each other such as to form a stem upon intramolecular hybridization,

the hybridization affinity of the central loop sequence to the region of the target nucleic acid molecule comprising the point mutation being higher than the intramolecular hybridization affinity of the 5′ sequence to the 3′ sequence, and

a non-extensible moiety capable of selectively hybridizing to the wild type nucleic acid molecules and of blocking amplification thereof.

2. The set of primers of claim 1 , wherein each of the 5′ end sequence and the 3′ end sequence of the stem-loop mutant extensible primer is at least 3 nucleotides in length.

3. The set of primers of claim 1 , further comprising a non extensible moiety capable of hybridizing to the wild type nucleic acid molecules.

4. The set of primers of claim 3 , wherein the non extensible moiety is a Peptide Nucleic Acid (PNA).

5. The set of primers of claim 4 , wherein the PNA is at least 10 bases in length.

6. The set of primers of claim 1 , wherein the nonextensible moiety is a stem-loop 3′ end modified wild type non-extensible primer, comprising:

a central loop sequence complementary to a region of the wild type nucleic acid molecules comprising the nucleic acid position of the point mutation to be detected;

a 5′ end sequence and a 3′ end sequence which are complementary to each other such as to form a stem upon intramolecular hybridization,

the hybridization affinity of the central loop sequence to the region of the wild type nucleic acid molecules comprising the nucleic acid position of the point mutation to be detected being higher than the intramolecular hybridization affinity of the 5′ end sequence to the 3′ end sequence.

7. The set of primers of claim 1 , wherein the first outer primer F3 comprises SEQ ID NO:3, the second outer primer B3 comprises SEQ ID NO:4, the first inner primer FIP comprises SEQ ID NO:5, the second inner primer BIP comprises SEQ ID NO:6 and the stem-loop mutant extensible primer comprises SEQ ID NO:8.

8. The set of primers of claim 7 , further comprising a non extensible moiety which is a PNA comprising the following base sequence:

(SEQ ID NO: 9)

NH2-GAGTATGTGTCTGTGGA-COOH.

9. A kit for detecting, by loop mediated isothermal amplification, the presence of a point mutation in a target nucleic acid molecule, the kit comprising the set of primers of claim 1 and a DNA polymerase having strand displacement activity.

10. The kit of claim 9 , wherein the DNA polymerase is selected from the group consisting of Bst large fragment polymerase, Bca (exo-), Vent, Vent (exo-), Deep Vent, Deep Vent (exo-), (I)29 phage, MS-2 phage, Z-Taq, KOD, Klenow fragment and any combination thereof.

11. The kit of claim 9 , further comprising one or more calibrators, wherein said one or more calibrators comprise a predetermined percentage of wild type nucleic acid molecules.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2023
From: DIASORIN IRELAND LIMITED
To: DIASORIN MOLECULAR LLC
Reel/Frame 064701/0749 →
CHANGE OF NAME Recorded Aug 25, 2023
From: BIOTRIN INTERNATIONAL LIMITED
To: DIASORIN IRELAND LIMITED
Reel/Frame 064701/0810 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2012
From: ADLERSTEIN, DANIEL; AMICARELLI, GIULIA; MINNUCCI, GIULIA
To: BIOTRIN INTERNATIONAL LIMITED
Reel/Frame 027515/0415 →
Priority Claims (1)
EP 09165252 · Jul 10, 2009 · regional
Continuity (1)
Related Publication 20120171676A1 · Jul 5, 2012